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ER81 is a transcription factor that may contribute to breast cancer; however, little known about the role of ER81 in breast
carcinogenesis. To investigate the role of ER81 in breast carcinogenesis, we examined ER81 expression in IDC, DCIS, ADH, HUT,
and normal breast tissues by immunohistochemical staining. We found that ER81 overexpression was detected in 25.7% (9/35)
of HUT, 41.2% (7/17) of ADH, 54.5% (12/22) of DCIS, and 63.0% (51/81) of IDC. In 20 of breast cancer tissues combined with
DCIS, ADH, and HUT, ER81 expression was found in 14/20 (70%) IDC. In these 14 cases all cases were ER81 positive expression
in DCIS, 13 of 14 cases were positively expressed of ER81 in ADH and 8 of 14 were positive for ER81 in HUT components. A
statistical signiﬁcance was found between NBT and HUT (P<. 05) and HUT and ADH (P<. 05). Clinical-pathological features
analysis of breast cancer revealed that ER81 expression was signiﬁcantly associated with Her2 ampliﬁcation and was negatively
associated with ER and PR expression. Our results demonstrated that ER81 overexpression was present in the early stage of breast
development that suggested that ER81 overexpression may play an important role in breast carcinogenesis.
1.Introduction
Breast carcinogenesis is thought to undergo a transition
from normal epithelium to invasive carcinoma (IDC) via
hyperplasia of usual type (HUT), atypical ductal hyperplasia
(ADH), and carcinoma in situ (DCIS) [1]. Over 14%
of breast cancer diagnosed in the United States annually
are DCIS, and approximately 50% of untreated DCIS will
develop into an IDC within 24 years after the original biopsy
[2]. However, it is unclear how IDC develop from these
lesions.
ER81 (ETS-related 81), also called ETS variant 1 (ETV1),
is a transcription factor that is a member of the ETS family
of DNA-binding proteins [3–5]. Its association with cancer
was ﬁrst noted in Ewing tumors, in which the EWS gene can
be translocated onto the ER81 gene and the resultant EWS-
ER81 fusion protein exerts oncogenic properties [6]. From
then on, many ﬁndings suggest that dysregulation of ER81
target genes in disparate tumors like Ewing sarcomas and
prostate carcinomas are causally involved in tumorigenesis
[7]. Of note, ER81 transcriptional activity is dramatically
enhanced upon Her2/Neu (a receptor tyrosine kinase and
proto-oncoprotein especially associated with breast cancer)
overexpression [8, 9]. Moreover, ER81 mRNA levels are
increased in murine cell lines and tumors overexpressing
Her2/Neu and also in many human breast cancer cell
lines, which suggests that ER81 may contribute to breast
tumorigenesis [10–12].
To gain more insight into ER81’s role in breast tumorige-
nesis, we attempted to examine ER81 expression in invasive
breast cancers, ductal carcinoma in situ, atypical ductal
hyperplasia, and hyperplasia without atypia and normal
breast tissues in this study.
2.MaterialsandMethods
2.1. Materials. Formalin-ﬁxed, paraﬃn-embedded tissue
specimens including 103 of primary breast cancers including
81 invasive ductal carcinomas (IDC) and 22 ductal carci-
nomas in situ (DCIS), 52 of breast hyperplasia including2 Pathology Research International
17 atypical ductal hyperplasia (ADH) and 35 hyperplasia of
usual type (HUT), and 62 of normal breast tissues (NBT)
were collected from Department of Pathology, Kunming
General Hospital and The First People’s Hospital of Yunnan
Province between June 2006 and October 2009. Further-
more, 20 paraﬃn-embedded tissue blocks of breast invasive
ductal carcinomas combined with ductal carcinomas in situ,
atypical Hyperplasia, hyperplasia of usual type, and normal
breast tissues were got from the two hospitals.
2.2. Immunohistochemical Staining. Immunohistochemistry
was employed to detect the expression of ER81 for all breast
tissues and the expression of ER, PR for all the 81 cases
of invasive ductal carcinomas tissues. EnVision Systems was
adopted for the staining. Brieﬂy, 4μm sections were taken
from formalin-ﬁxed, paraﬃn-embedded tissue blocks. The
deparaﬃnized sections were pretreated with heat-induced
epitope retrieval and then treated with 30mL/L hydrogen
peroxidase in methanol for 30min to block endogenous
peroxidase activity. The sections were further blocked with
10mL/L normal goat serum for 30min, followed by incu-
bation with primary antibody (mouse antihuman mono-
clonal antibody ER81, SANTA CRUZ BIOTECHNOLOGY,
INC; mouse antihuman monoclonal antibody ER and PR,
Maixin-Bio, Fuzhou, China) at 4◦C overnight. The sections
were then washed in 0.01mol/L phosphate buﬀer solutions
(PBS, pH 7.2) and sequentially incubated with Envision
(Envision kit, DakoCytomation, Inc, Carpinteria, California,
USA) for 30min. The reaction product was visualized by
diaminobenzidine tetrahydrochloride (DAB). All slides were
counterstainedwithhematoxylin,dehydrated,andmounted.
PBS substituting for the primary antibody was used as the
negative control.
2.3. Assessment of Immunohistochemical Staining. Speciﬁc
staining was evaluated independently by two investigators.
We used a semiquantitative manner to assess the ER81
staining, yielding an immunoreactive score (IRS) ranging
from 0 to 9. IRS was calculated by multiplying the num-
ber of positive cytoplasmic staining of cells (0 = none,
1 =< 10%, 2 = 10–50%, 3 => 50% positive tumor cells) by
the staining intensity (1 = weak, 2 = moderate, 3 = strong).
Then we considered IRS 0 score as ER81 expression “−”, IRS
1-2 score as ER81 expression “+”, IRS 3–5 score as ER81
expression “++”, IRS 6–9 score as ER81 expression “+++”.
Positive reaction in a normal epithelium yielded a maximum
IRSof 2. Thereforebreasthyperplastic cellsand breast cancer
cells in other groups were considered ER81 positive with
IRS ≥ 3 as suggested by Going et al. [13]. The ER and
PR positive staining should be localized to the nucleus.
Specimens in which more than 10% of cells showed positive
immunoreactivity were considered to be immunoreactive.
2.4. Fluorescence In Situ Hybridization (FISH). AH E R 2 / n e u
probe kit (China Medical Technologies, Inc, Beijing, China)
wasusedforFISHanalysisforallthe81casesofinvasiveduc-
tal carcinomas tissues. Tissue sections were baked overnight
at 56◦C, dewaxed in xylene, dehydrated and air-dried. The
Table 1: ER81 expression in breast cancers and hyperplasia (n,% ) .
− + ++ +++ Total
NBT 45 (72.6) 17 (27.4) 0 (0.0) 0 (0.0) 62
HUT 6 (17.1) 20 (57.1) 9 (25.8) 0 (0.0) 35
ADH 2 (11.8) 8 (47.1) 6 (35.3) 1 (5.9) 17
DCIS 2 (9.1) 8 (36.4) 8 (36.4) 4 (18.2) 22
IDC 2 (2.5) 28 (34.6) 32 (39.5) 19 (23.4) 81
slides were then pretreated with sodium bisulﬁte at 50◦C
for 30min and digested with protease K for 15min at
37◦C and ﬁnally hybridized overnight at 42◦C with the
probes (GLP HER2/CSP17 DNA probe, China Medical
Technologies, Inc, Beijing, China) after DNA denaturation
at 73◦C. Slides were washed with posthybridization buﬀer
at 73◦C, counterstained with 4, 6-diamidino-2-phenylindole
(DAPI) and mounted and stored in the dark prior to signal
enumeration. For FISH analysis, slides were examined with
ﬂuorescence microscope. Areas of optimal tissue digestion
and no overlapping nuclei were then selected in each core for
counting. 30 cells were counted for each case. We considered
caseswithaFISHratio(Her2genesignalstochromosome17
signals) of ≥2.2 as Her2 ampliﬁed.
2.5. Statistical Analysis. The statistical analysis was per-
formed using the SPSS software package, version 11.0. The
diﬀerences were analyzed by Kruskal-Wallis (K-W or H) test
and Pearson chi-squared distribution (χ2) test. A value of
P<. 05 was considered statistically signiﬁcant.
3. Results
Formalin-ﬁxed tissue sections from a spectrum of mammary
lesions were analyzed for ER81 expression. As shown in
Table 1 and Figures 1, 2,a n d3, 72.6% normal breast
specimens were completely negative for reactivity to ER81,
and the rest of the cases reacted very slightly yielding a
maximum IRS of 2. Hyperplastic lesions without atypical
demonstrated slightly higher levels of ER81 expression than
did in nonhyperplasia (P<. 01) with an average IRS of
1.77 for ER81. In 9 of 35 specimens, hyperplastic epithelium
demonstrated IRS = 3, whereas all of the remaining cases
were IRS ≤ 2. Hyperplastic lesions with atypical generally
demonstrated slightly higher levels of ER81 expression than
did in nonatypical hyperplastic epithelium (P<. 01) and
nonhyperplasia epithelium (P<. 01) with an average IRS of
2.53 for ER81. 6 of 17 atypical hyperplasia cases were ER81
expression “++” and 1 case was ER81 expression “+++”
with IRS = 6. Ductal carcinoma in situ tissues generally
demonstrated slightly higher ER81 expression than did in
atypicalhyperplasiawithanaverageIRSof3.18forER81,but
the diﬀerence is not statistically signiﬁcant (P>. 05). 4 of 22
(18.2%)ductalcarcinomainsitutissueswasER81expression
“+++” and 8 of 22 (36.4%) cases were ER81 expression
“++”. Invasive ductal carcinomas demonstrated enhanced
levels of ER81 expression. The expression of ER81 in invasive
ductal carcinomas was statistically diﬀerent from that inPathology Research International 3
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Figure 1: ER81 expression in breast cancers and hyperplasia. (a) Negative expression of ER81 in hyperplasia of usual type (×400). (b)
Positive expression of ER81 in atypical ductal hyperplasia (×400). (c) Positive expression of ER81 in ductal carcinoma in situ (×400). (d)
Positive expression of ER81 in invasive ductal carcinoma (×400).
NBT HUT ADH DCIS IDC
0
2
4
6
8
10
E
R
8
1
I
R
S
127 214 207
206 200
Figure 2: Comparison of ER81 expression in breast cancers and
hyperplasia. The box plot markings represent median, 25–75th
percentile, and the range of all values.
ductal carcinomas in situ, atypical ductal hyperplasia tissues,
hyperplasia cases of usual type, and normal breast tissues
(P<. 01). The average IRS of invasive ductal carcinomas
for ER81 was 3.74, and 19 of 81 cases (23.4%) showed ER81
expression “+++”. The IRS of carcinoma cells varied from 0
t o9w i t h5 1o f8 1c a s e s( 6 2 . 9 % )d e m o n s t r a t i n gI R S≥ 3f o r
ER81 expression.
The above data provided lines of evidence that ER81
overexpression happened in the early stage of breast cancer
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Figure 3:ThedistributionofER81expressioninbreastcancersand
hyperplasia. Each dot represents ER81 IRS of one case.
development. In order to conﬁrm the association between
ER81 expression and breast tumorigenesis, we employed 20
IDC tissues combined with DCIS, ADH, HUT, and NBT to
examine ER81 expression. We considered a threshold IRS
set at ≥3 as ER81 positive expression. In this group, ER81
expression was found in 14/20 (70%) IDC. In these 14
cases, ER81 expression was found in 14/14 of adjacent DCIS,4 Pathology Research International
Table 2: ER81 expression in breast cancers combined with DCIS
and benign breast hyperplasia (n,% ) .
− + ++ +++ Total
NBT 5 (25.0) 15 (75.0) 0 (0.0) 0 (0.0) 20
HUT 4 (20.0) 8 (40.0) 8 (40.0) 0 (0.0) 20
ADH 3 (15.0) 2 (10.0) 11 (55.0) 4 (20.0) 20
DCIS 2 (10.0) 2 (10.0) 10 (50.0) 6 (30.0) 20
IDC 1 (5.0) 5 (25.0) 8 (40.0) 6 (30.0) 20
13/14 adjacent ADH, and 8/14 adjacent HUT components.
Adjacent normal breast component demonstrated ER81
negative expression. By K-W analysis for the expression level
of ER81, we found a statistical signiﬁcance between NBT
and HUT (P<. 05) and HUT and ADH (P<. 05), but no
statistical signiﬁcance was found between ADH and DCIS
(P>. 05) or DCIS and IDC (P>. 05) (Table 2 and Figures
4, 5).
The relationship between ER81 expression and clinical-
pathological features such as ER, PR, and Her2 in breast
cancer is listed in Table 3. The results revealed that ER81
expression was signiﬁcantly associated with Her2 ampliﬁca-
tion and was negatively associated with ER and PR expres-
sion.NocorrelationwasfoundbetweenER81expressionand
patient ages, menopause status, tumor sizes, nodal status,
and histological stage (Table 3).
4. Discussions
Increasing lines of evidence suggest that breast cancer
develop through a multistep model of carcinogenesis, that is,
from normal breast epithelia to hyperplasia without atypia,
hyperplasia with atypia, ductal carcinoma in situ, to invasive
carcinoma [1, 14, 15]. In experiments carried out by DeOme
et al. [16], when hyperplastic breast alveolar nodules (HAN),
the breast epithelial cells infected by murine mammary
tumor virus, were transplanted to cleared mammary fat
pads, half of them developed into carcinomas by 13–
21 weeks, which happened more frequently than normal
breast tissues. In breast biopsies harbouring malignancy,
inﬁltrating carcinoma is often found side-by-side with in
situ carcinoma and/or benign proliferations. These lesions
occasionally show morphological transition and continuity
with the invasive carcinoma. Karpas et al. [17]e v a l u a t e d
645 breast biopsies (226 malignant and 419 benign) and
found atypical hyperplasia in 62% of malignant biopsies, but
only in 4% of benign biopsies. Similarly, Kern and Brooks
[18] found a greater incidence of atypical ductal hyperplasia
(ADH) in cancer-bearing breasts. Foote and Stewart [19]
found that papillary hyperplasia with atypia occurred ﬁve
times more frequently in the cancerous breasts. In a similar
study, Ryan and Coady [20] found that hyperplasia was
four times more common in the cancerous breasts. These
histopathological studies data provide convincing evidence
that some forms of proliferative lesions are often found in
association with invasive cancer and that ADH provides a
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Figure 4: Comparison of ER81 expression in breast cancers
combined with DCIS and benign breast hyperplasia. The box plot
markings represent median, 25–75th percentile, and the range of all
values.
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Figure 5: The distribution of ER81 expression in breast cancers
combined with DCIS and benign breast hyperplasia. Each dot
represents ER81 IRS of one case.
signiﬁcantly increased relative risk of subsequent invasive
carcinoma. However, little is known about the molecular
genetic mechanisms involved in the transformation from
hyperplasia to cancer, which is important for the early
diagnosis and molecularly targeted therapy of breast cancers
[21].
ER81 is a downstream gene of Her2/ N e u ,ar e c e p t o rtyr o -
sine kinase and proto-oncoprotein. And Her2 is especially
associated with breast cancer. Of note, ER81 transcriptional
activity is dramatically enhanced upon Her2/Neu overex-
pression [8, 9]. On the other hand, ER81 can target Her2
and upregulate Her2 expression in breast tumors, suggesting
the existence of a feed-forward loop in the upregulation ofPathology Research International 5
Table 3: Comparison between ER81 expression and clinical data in
breast cancers.
n ER81 negative
(%)
ER81 positive
(n,% ) ∗ P (χ2)
Age, years
≤50 48 22 (45.8) 26 (54.2) .814
>50 33 16 (48.5) 17 (51.5)
Menopause
Before 46 22 (47.8) 24 (52.2) .483
After 35 14 (40.0) 21 (60.0)
Tumor size, cm
≤21 5 7 (46.7) 8 (53.3)
.138 2–5 55 28 (50.9) 27 (49.1)
>51 1 2 (18.2) 9 (81.8)
Nodal status
Negative 43 18 (41.9) 25 (58.1) .463
Positive 38 19 (50.0) 19 (50.0)
Histological stage
I1 0 6 (60.0) 4 (40.0)
.246 II 54 14 (25.9) 30 (74.1)
III 17 6 (35.3) 11 (64.7)
ER
Negative 25 1 (4.0) 24 (96.0) .001
Positive 56 22 (39.3) 34 (60.7)
PR
Negative 28 3 (10.7) 25 (89.3) .010
Positive 53 20 (37.7) 33 (62.3)
HER2 ampliﬁcation
Negative 53 19 (35.8) 34 (64.2) .041
Positive 28 4 (14.3) 24 (85.7)
∗BreastcancertissueswithIRS ≥ 3wereconsideredasER81positiveexpres-
sion.
HER2/Neu [22]. Moreover, ER81 mRNA levels are increased
in murine cell lines and tumors overexpressing Her2/Neu
and also in many human breast cancer cell lines, suggesting
that ER81 may contribute to breast tumorigenesis [10–
12]. Shin et al. found that ER81 downregulation suppresses
proliferation of Her2-positive MDA-MB-231 breast cancer
cells in vitro and tumor formation in vivo, proving for
the ﬁrst time the existence of a critical role of ER81
in breast cancer cell physiology [5]. Although transgenic
mice overexpressing ER81 in the breast do not develop
mammary tumors, ER81 overexpression may prime breast
cells to become malignant, for instance upon additional
overexpression of Her2/Neu [5].
In this study, we investigated the role of ER81 in
breast carcinogenesis by two steps: (1) examining ER81
overexpression in IDC, DCIS, ADH, HUT, and normal
breasttissueswhichrepresentsdiﬀerentstageofbreastcancer
development. As a result, weak staining was observed in
normal breast tissues yielding a maximum IRS of 2. If cells
in other groups were considered ER81 positive with IRS ≥ 3,
ER81 overexpression was detected in 25.7% (9/35) of HUT,
41.2% (7/17) of ADH, 54.5% (12/22) of pure DCIS, and
63.0% (51/81) of IDC. Although there was ER81 expression
inHUT,allER81positivetissuesweremoderatestaining.The
expression level of ER81 was increased with the progression
of the lesion. It is implied that ER81 overexpression are
present in the early stage of breast development. (2) Exam-
ining ER81 overexpression in breast cancer and the adjacent
hyperplasic components (each component represents one
stage of breast cancer development) in a single tumor. In
this group, ER81 expression was found in 70% (14/20) IDC.
In these 14 cases all cases were ER81 positive expression
in DCIS, 13 of 14, cases were positively expressed of ER81
in ADH, and 8 of 14 were positive for ER81 in HUT
components. A statistical signiﬁcance was found between
NBT and HUT (P<. 05) and HUT and ADH (P<. 05),
but no statistical signiﬁcance was found between ADH and
DCIS (P>. 05) or DCIS and IDC (P>. 05) conﬁrming that
ER81 may involve in breast carcinogenesis.
In addition, we analyzed the relationship between ER81
expression and clinical-pathological features of breast cancer
including Her2 ampliﬁcation and ER, PR expression. The
results revealed that ER81 expression was signiﬁcantly asso-
ciated with Her2 ampliﬁcation and was negatively associated
with ER and PR expression. No correlation was found
between ER81 expression and patient ages, menopause
status, tumor sizes, nodal status, and histological stage. In
Her2 positive ampliﬁcation group, the number of ER81
positive expressed cases was more than that in Her2 negative
ampliﬁcation group. As we know, overexpression of ER81 in
itself does not lead to breast tumor formation [23], possibly
because ER81 requires stimulation in order to become
transcriptionally competent and the activation of ER81 is
inducible by the Her2→Ras→Raf→MAP kinase signaling
pathway[9,24,25].TheseresultssuggestthatHer2 andER81
synergize breast carcinogenesis.
Conclusively, ER81 overexpression was present in the
early stage of breast development. Together with previous
studyresults,itissuggestedthatER81mayplayanimportant
role in breast carcinogenesis.
Abbreviations
IDC: invasive ductal carcinoma
DCIS: ductal carcinoma in situ
ADH: atypical ductal hyperplasia
HUT: hyperplasia of usual type
NBT: normal breast tissue
IRS: immunoreactive score
ER: estrogen receptor
PR: progesterone receptor.
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